CorMedix Statistics
Total Valuation
CorMedix has a market cap or net worth of $520.00 million. The enterprise value is $474.53 million.
Important Dates
The last earnings date was Wednesday, October 30, 2024, before market open.
Earnings Date | Oct 30, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
CorMedix has 60.68 million shares outstanding. The number of shares has increased by 23.09% in one year.
Current Share Class | 60.68M |
Shares Outstanding | 60.68M |
Shares Change (YoY) | +23.09% |
Shares Change (QoQ) | +2.09% |
Owned by Insiders (%) | 0.95% |
Owned by Institutions (%) | 31.96% |
Float | 60.10M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 12.98 |
PS Ratio | 40.44 |
Forward PS | 3.74 |
PB Ratio | 8.45 |
P/TBV Ratio | 9.15 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 38.70 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.96, with a Debt / Equity ratio of 0.01.
Current Ratio | 3.96 |
Quick Ratio | 3.43 |
Debt / Equity | 0.01 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -1,546.43 |
Financial Efficiency
Return on equity (ROE) is -65.04% and return on invested capital (ROIC) is -44.49%.
Return on Equity (ROE) | -65.04% |
Return on Assets (ROA) | -37.69% |
Return on Capital (ROIC) | -44.49% |
Revenue Per Employee | $147,738 |
Profits Per Employee | -$556,005 |
Employee Count | 83 |
Asset Turnover | 0.15 |
Inventory Turnover | n/a |
Taxes
Income Tax | -1.39M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +143.47% in the last 52 weeks. The beta is 1.53, so CorMedix's price volatility has been higher than the market average.
Beta (5Y) | 1.53 |
52-Week Price Change | +143.47% |
50-Day Moving Average | 10.35 |
200-Day Moving Average | 6.57 |
Relative Strength Index (RSI) | 40.01 |
Average Volume (20 Days) | 945,526 |
Short Selling Information
The latest short interest is 6.89 million, so 11.36% of the outstanding shares have been sold short.
Short Interest | 6.89M |
Short Previous Month | 6.84M |
Short % of Shares Out | 11.36% |
Short % of Float | 11.47% |
Short Ratio (days to cover) | 5.12 |
Income Statement
In the last 12 months, CorMedix had revenue of $12.26 million and -$46.15 million in losses. Loss per share was -$0.80.
Revenue | 12.26M |
Gross Profit | 10.25M |
Operating Income | -50.96M |
Pretax Income | -51.63M |
Net Income | -46.15M |
EBITDA | -50.77M |
EBIT | -50.96M |
Loss Per Share | -$0.80 |
Full Income Statement Balance Sheet
The company has $46.03 million in cash and $556,416 in debt, giving a net cash position of $45.47 million or $0.75 per share.
Cash & Cash Equivalents | 46.03M |
Total Debt | 556,416 |
Net Cash | 45.47M |
Net Cash Per Share | $0.75 |
Equity (Book Value) | 58.71M |
Book Value Per Share | 1.01 |
Working Capital | 54.67M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$55.75 million and capital expenditures -$401,792, giving a free cash flow of -$56.15 million.
Operating Cash Flow | -55.75M |
Capital Expenditures | -401,792 |
Free Cash Flow | -56.15M |
FCF Per Share | -$0.93 |
Full Cash Flow Statement Margins
Gross Margin | 83.57% |
Operating Margin | -415.59% |
Pretax Margin | -387.72% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
CorMedix does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -23.09% |
Shareholder Yield | -23.09% |
Earnings Yield | -8.87% |
FCF Yield | -10.80% |
Analyst Forecast
The average price target for CorMedix is $15.80, which is 84.36% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $15.80 |
Price Target Difference | 84.36% |
Analyst Consensus | Strong Buy |
Analyst Count | 5 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
The last stock split was on March 26, 2019. It was a reverse split with a ratio of 0.2:1.
Last Split Date | Mar 26, 2019 |
Split Type | Reverse |
Split Ratio | 0.2:1 |
Scores
CorMedix has an Altman Z-Score of 0.1 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 0.1 |
Piotroski F-Score | 1 |